Novartis’ groundbreaking CAR-T cancer therapy is one big step closer to reaching patients.

A panel of outside experts convened by the FDA voted 10-0 Wednesday to recommend the approval of Novartis’ CAR-T therapy, called CTL019, for the treatment of children and young adults with advanced leukemia. The vote marks a pivotal milestone for this class of experimental treatment. The FDA is expected to make a final decision on approval by Oct. 3.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

    • Yes, CTL019 can work against any malignancy that expresses CD19, which would be any B cell malignancy such as ALL, CLL, and various B cell lymphomas. It also works against multiple myeloma, but they are not certain why it works. It either attacks a CD19+ precursor, or MM cells express CD19 briefly or at low levels and get killed off.

  • You should know the truth about CANCER. There are so many different therapies & drugs out there, far better to avoid Cancer. Spirit know what causes CANCER so people are not confused about it.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy